Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 23,124 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 23,124 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $425,640. This represents a 85.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Dianthus Therapeutics Price Performance

NASDAQ DNTH traded up $1.61 on Thursday, hitting $107.85. 355,690 shares of the stock were exchanged, compared to its average volume of 931,557. The business’s fifty day moving average is $104.65 and its 200 day moving average is $88.52. Dianthus Therapeutics, Inc. has a 52 week low of $23.70 and a 52 week high of $117.88. The company has a market capitalization of $5.90 billion, a PE ratio of -25.99 and a beta of 1.24.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. ABS Investment Management LLC acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $194,960,000. First Horizon Corp bought a new position in Dianthus Therapeutics in the 1st quarter valued at about $32,000. EFG International AG acquired a new stake in Dianthus Therapeutics during the second quarter worth approximately $49,000. Global Retirement Partners LLC acquired a new stake in Dianthus Therapeutics during the second quarter worth approximately $93,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $40,000. Institutional investors own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

DNTH has been the subject of a number of research analyst reports. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. HC Wainwright upped their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wedbush raised their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $124.27.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.